Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs ProShares Ultra QQQ ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while ProShares Ultra QQQ ETF trades at $91.63. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| BIO | QLD | |
|---|---|---|
Market Cap | $9.39B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $356.25 | $100.53 |
52-Week Low | $241.71 | $57.16 |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
QLD, the ProShares Ultra QQQ ETF, trades at $92.2, up 2.3% today, reflecting strong bullish momentum. Technical indicators show a bullish moving average consensus and key support at $91, with resistance at $93. Recent institutional buying, including a 29.4% stake increase by 180 Wealth Advisors in Q2 2026, underscores confidence. The ETF has delivered over 10,000% total return since inception, though its leveraged structure amplifies volatility.
The outlook for QLD is cautiously optimistic, driven by tech sector strength and tactical ETF demand. However, risks include amplified losses during market downturns, with a historical maximum drawdown of 63.80%. Investors should weigh the potential for outsized gains against the inherent volatility of daily leveraged products in a shifting economic landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
